학술논문

Development of the Facial Skin Care Index: A Health-Related Outcomes Index for Skin Cancer Patients
Document Type
Author abstract
Source
Dermatologic Surgery. July, 2006, Vol. 32 Issue 7, p924, 11 p.
Subject
Skin cancer -- Patient outcomes
Skin cancer -- Care and treatment
Cancer patients -- Patient outcomes
Cancer patients -- Care and treatment
Skin -- Care and treatment
Dermatology -- Formulae, receipts, prescriptions
Dermatologic agents
Toiletries industry
Language
English
ISSN
1076-0512
Abstract
To purchase or authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1524-4725.2006.32197.x Byline: B ALEX MATTHEWS (*), JOHN S RHEE ([dagger][double dagger]), MARCY NEUBURG ([double dagger]), MARY L BURZYNSKI ([dagger]), ANN B NATTINGER (*s.) Abstract: BACKGROUND Existing health-related quality-of-life (HRQOL) tools do not appear to capture patients' specific skin cancer concerns. OBJECTIVE To describe the conceptual foundation, item generation, reduction process, and reliability testing for the Facial Skin Cancer Index (FSCI), a HRQOL outcomes tool for skin cancer researchers and clinicians. METHODS Participants in Phases I to III consisted of adult patients (N=134) diagnosed with biopsy-proven nonmelanoma cervicofacial skin cancer. Data were collected via self-report surveys and clinical records. RESULTS Seventy-one distinct items were generated in Phase I and rated for their importance by an independent sample during Phase II; 36 items representing six theoretical HRQOL domains were retained. Test-retest I results indicated that four subscales showed adequate reliability coefficients ([alpha]=0.60 to 0.91). Twenty-six items remained for test-retest II. Results indicated excellent internal consistency for emotional, social, appearance, and modified financial/work subscales (range 0.79 to 0.95); test-retest correlation coefficients were consistent across time (range 0.81 to 0.97; lifestyle omitted). CONCLUSION Pretesting afforded the opportunity to select items that optimally met our a priori conceptual and psychometric criteria for high data quality. Phase IV testing (validity and sensitivity before surgery and 4 months after Mohs micrographic surgery) for the 20-item FSCI is under way. Author Affiliation: (*)Health Policy Institute, Center for Patient Care & Outcomes Research ([dagger])Department of Otolaryngology and Communication Sciences ([double dagger])Department of Dermatology (s.)Department of Medicine, General Internal Medicine, Froedtert Memorial Lutheran Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin Article note: Address correspondence and reprint requests to: B. Alex Matthews, PhD, Center for Patient Care & Outcomes Research, Suite H2755, Medical College of Wisconsin, 8701 Watertown Plank Road, PO Box 26509, Milwaukee, WI 53226-0509, or e-mail: amatthew@mcw.edu.